MET and cholangiocarcinoma: A phase II study investigated the multikinase inhibitor cabozantinib in pretreated, unselected patients with advanced CCA resulting in limited activity with high toxicity.18 However, one patient considered to have high MET expression (3+ by immunohistochemical (IHC) analysis) experienced a prolonged benefit and duration of treatment.